logo
PayPal to launch cross-border platform with link to India's UPI payments system

PayPal to launch cross-border platform with link to India's UPI payments system

Reuters23-07-2025
MUMBAI, July 23 (Reuters) - Payments firm PayPal has partnered with the operator of India's popular unified payments interface and others to launch a global platform through which consumers can make cross-border payments to businesses.
The platform, PayPal World, will enable interoperability between local payment platforms and PayPal, the firm said in a statement on Wednesday.
Its partners for the platform include National Payments Corporation of India - India's payments authority that operates UPI, Brazil's Mercado Pago, Tencent Holdings' (0700.HK), opens new tab Tenpay Global and Venmo.
UPI dominates digital payments in India, accounting for about 85% of the total volume of retail digital payments, per regulatory data.
"The integration of UPI on PayPal World's platform will mark a significant step in expanding UPI's global footprint," said Ritesh Shukla, managing director and CEO of NPCI International Payments Limited.
India has been in talks with countries in Africa and South America to help them build a digital payments system using UPI as a blueprint.
PayPal's platform is expected to go live later this year. The firm intends to add more partners going forward.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bunge Q2 profit beats estimates after soy crush margin rebound
Bunge Q2 profit beats estimates after soy crush margin rebound

Reuters

timean hour ago

  • Reuters

Bunge Q2 profit beats estimates after soy crush margin rebound

July 30 (Reuters) - U.S. grain trader and processor Bunge Global (BG.N), opens new tab reported a smaller-than-expected drop in second-quarter profit on Wednesday after soy crush margins jumped late in the quarter. The world's largest oilseed processor benefited as soybean prices dropped and soyoil prices rallied on favorable biofuel policy moves in the United States and Brazil. Better results in Bunge's grains and oils merchandising business also blunted the negative impact from ongoing global trade uncertainty as U.S. President Donald Trump's tariff threats upended global commodity flows. Bunge shares were up 2.85% at $78.56 in early trading. "We successfully navigated a highly complex period, both internally and externally, and delivered better-than-expected results for the quarter, especially given the market conditions," CEO Greg Heckman said. The earnings beat came as Bunge secured final regulatory approvals for its long-delayed deal to acquire grain handler Viterra, a transaction that officially closed at the start of the third quarter on July 2. It also completed the sale of its U.S. corn milling business. Bunge maintained its 2025 earnings guidance of $7.75 per share, which would be its lowest in six years, but said it would update it to include the Viterra merger prior to reporting third-quarter results. Bunge and agribusiness peers including Archer-Daniels-Midland (ADM.N), opens new tab and Cargill have seen profits erode in recent quarters due to ample global crop supplies and thinning margins. Trade tensions stoked by Trump's tariffs have further disrupted trade flows as importing nations bought hand to mouth amid the U.S. president's shifting deadlines for imposing duties. Meanwhile, biofuel policy uncertainty dented demand for green energy feedstocks like soybean oil, although proposed increases for biofuel blending in the U.S. and Brazil was supportive in the longer term for Bunge. "We expect challenging conditions to persist," said CFRA analyst Arun Sundaram, citing tariffs and inflation. "We anticipate more clarity on biofuel policy in coming quarters, which could provide some relief to the current soft macro environment." Bunge posted an adjusted profit of $1.31 per share for the three months ended June 30, compared with analysts' average estimate of $1.14, according to data compiled by LSEG.

Trump frustrated with India talks, will detail additional penalty soon, adviser says
Trump frustrated with India talks, will detail additional penalty soon, adviser says

Reuters

timean hour ago

  • Reuters

Trump frustrated with India talks, will detail additional penalty soon, adviser says

WASHINGTON, July 30 (Reuters) - U.S. President Donald Trump has been frustrated with how trade talks with India are progressing and believes his 25% tariff announcement will help the situation, White House economic adviser Kevin Hassett said on Wednesday. Trump and U.S. Trade Representative Jamieson Greer will have more information "shortly" on the additional penalty Trump announced earlier, Hassett told reporters at the White House. "I think President Trump is frustrated with the progress we've made with India but feels that a 25% tariff will address and remedy the situation in a way that's good for the American people," Hassett said. Trump said in a post on Truth Social earlier Wednesday he would impose a 25% tariff on goods imported from India, starting Aug. 1. He added that the world's fifth-largest economy would also face an unspecified penalty, also starting on Friday, but gave no details.

Indian drugmaker JB Chem posts first-quarter profit jump on strong domestic demand
Indian drugmaker JB Chem posts first-quarter profit jump on strong domestic demand

Reuters

timean hour ago

  • Reuters

Indian drugmaker JB Chem posts first-quarter profit jump on strong domestic demand

July 30 (Reuters) - Indian drugmaker JB Chemicals & Pharmaceuticals ( opens new tab reported an 8.9% higher first-quarter profit on Wednesday, led by healthy domestic demand for its drugs. The maker of "Rantac" antacid reported a consolidated net profit of 2.02 billion rupees ($23.02 million) for the quarter ended June 30, compared with 1.77 billion rupees a year earlier. Its overall revenue climbed 14.5% to 10.94 billion rupees, boosted by demand in its key domestic formulations business. The Indian pharmaceutical market grew 8% in June, led by drugs treating chronic conditions such as hypertension and diabetes, benefitting drugmakers specialising in such treatments. JB Chem's revenue from its chronic and acute portfolios surged 15% and 12%, respectively, while an 8% climb in its contract drug manufacturing business also aided its results. PEER COMPARISON * The mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell ** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT APRIL TO JUNE STOCK PERFORMANCE -- All data from LSEG ($1 = 87.7400 Indian rupees)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store